6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Eidos Therapeutics, Inc.

101 Montgomery Street
Suite 2000
San Francisco, CA 94104
United States
415 887 1471

Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Dr. Neil KumarCEO & Director247.68kN/A1979
Dr. Uma SinhaChief Scientific Officer & Director533.4kN/A1957
Dr. Cameron Turtle Ph.D.Chief Bus. Officer578.4kN/A1990
Dr. Jonathan C. Fox FACC, M.D., Ph.D.Pres & Chief Medical OfficerN/AN/A1957
Dr. Isabella Graef M.D.Co-Founder & Board AdvisorN/AN/A1965
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

Corporate Governance

Eidos Therapeutics, Inc.’s ISS Governance QualityScore as of December 6, 2019 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.